Sir, We have read with great interest papers published concerning the efficacy and safety of tigecycline and the ensuing correspondence. Mortality has been reported in most of the publications to be higher with tigecycline in comparison with other antimicrobial agents. However, we would like to make some remarks on the role of superinfection rates during treatment with tigecycline, and the impact on safety.
Tigecycline was approved by the US FDA for the treatment of complicated skin and skin structure infections and complicated intra-abdominal infections (2005) , and for community-acquired pneumonia (2009). Due to the high rates of multidrug-resistant (MDR) pathogens and the scarcity of new antibacterial agents, the use of tigecycline was extended to the treatment of colistinresistant Acinetobacter baumannii infections, and as an alternative for patients allergic to b-lactam antimicrobial agents, by the Commission of Infections and Antimicrobial Policy in our hospital.
In January 2010 the FDA warned against using tigecycline in pulmonary infections because of increased mortality risk.
1 A recently published meta-analysis 2 concluded that tigecycline is not better than standard antimicrobial agents for the treatment of serious infections. Mortality from all causes was higher in the tigecycline group, although the difference was not statistically significant. On the other hand, they reported that an important advantage of tigecycline is that it can be used as monotherapy because it has a broad spectrum of antimicrobial activity. Despite this, their meta-analysis focused on randomized trials of only a few MDR infections.
Tigecycline has broad-spectrum in vitro activity against methicillin-resistant Staphylococcus, penicillin-resistant Streptococcus pneumoniae, vancomycin-resistant Enterococcus spp. and most Enterobacteriaceae, including extended-spectrum b-lactamase-producing strains. Tigecycline is also active against A. baumannii, including MDR strains. Proteus spp., Providencia spp., Morganella spp. and Stenotrophomonas maltophilia have reduced susceptibility. Pseudomonas aeruginosa is intrinsically resistant.
In order to evaluate the rate of superinfections due to the emergence of tigecycline resistance, we performed a retrospective and observational study of 51 patients treated with tigecycline.
3 The overall 30 day mortality was 23.5% (12/51). The superinfection rate during tigecycline treatment was 23.5% (12/51), with P. aeruginosa being responsible for 58.3% (7/12) of the superinfections.
With the aim of confirming these results, we extended the cohort in a prospective study (1 November 2008 to 31 January 2010). Tigecycline was prescribed as the treatment for nosocomial infections in 74 patients in this period. The method and definitions for this study were the same as those used in the previous study.
3 The overall 30 day mortality was 28.4% (21/ 74). The superinfection rate during tigecycline treatment was 24.3% (18/74), with P. aeruginosa being responsible for 33.3% (6/18) of the superinfections.
In the overall results, superinfection was observed in 24.0% (30/125) of the patients treated with tigecycline. P. aeruginosa was isolated in 13 patients (10.4%); the other 17 superinfections (13.6%) were caused by Proteus mirabilis (4), Enterobacter cloacae, Morganella morganii (2), Enterococcus faecalis (2), Providencia stuartii, Klebsiella pneumoniae (5), Escherichia coli and S. maltophilia. The characteristics and outcomes of the 30 patients with superinfections are detailed in Table 1 . Nine patients with superinfections died (30.0%).
The data collected during the 27 months of our study suggest that tigecycline may increase the number of superinfections caused by intrinsically resistant microorganisms (e.g. P. aeruginosa) or by microorganisms with reduced susceptibility to tigecycline (e.g. Proteus spp., K. pneumoniae, S. maltophilia, M. morganii, Enterobacter spp.). Concerning tigecycline's safety, it is important to underline the role of superinfections, both related and not related to mortality. In the overall results mortality was 26.4% (33/125), 4% (5/125) of which was in patients with superinfection. Yahav et al. 4 reported that superinfections were significantly more common in the tigecycline group than in the comparison groups, and clinical failure rates were significantly higher in the subgroup of patients with Gram-negative infections. Superinfections have been reported as adverse events in several tigecycline reviews, and we think that it is important to note the role of superinfection in order to prescribe tigecycline with other antibiotics for strains with known resistance, such as P. aeruginosa. Other authors 5, 6 have warned about the use of tigecycline in cystic fibrosis, as P. aeruginosa is still the most commonly isolated pathogen from the sputum of cystic fibrosis patients. Curcio 7 reported the need to reduce and rationalize the gap in the evidence from tigecycline clinical trials, which include nonseverely ill patients, and to place value on all of this in a scenario of high rates of MDR pathogens.
In conclusion, the rate of superinfection during treatment with tigecycline is higher than expected, and we think that it is important to note the role of superinfection both related and not related to mortality in the case of tigecycline use. More studies are needed to clarify the use of tigecycline in patients with severe infections.
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